1. Introduction {#s1}
===============

Acute exacerbations of bronchoconstriction may be severe, life-threatening, and refractory to conventional bronchodilator therapy. Treatments for severe bronchoconstriction may involve inhaled β~2~-agonists or helium--oxygen mixtures, short-term infusions of magnesium sulfate, or more invasive techniques such as extracorporeal membrane oxygenation \[[@bib1],[@bib2]\]. A clinically relevant alternative treatment strategy is the use of inhaled volatile anesthetic agents such as halothane, isoflurane, sevoflurane, or desflurane, since all are potent bronchodilators \[[@bib3]--[@bib7]\]. As described in multiple case reports and small series \[[@bib8]--[@bib12]\], treatment with volatile anesthetics generally results in improvement within 12 h. However, these agents have been used for periods of several days in refractory cases. Volatile anesthetics have also been shown to be effective in pediatric and obstetric patients \[[@bib5]--[@bib7],[@bib13]--[@bib15]\]. Reduced hospital length of stay and duration of mechanical ventilation have also been observed in patients treated with inhaled isoflurane \[[@bib16]\].

Despite their therapeutic potential, routine clinical use of inhaled anesthetic agents may be limited by predictable hemodynamic and sedative side effects \[[@bib1]\], especially in patients without a secured airway. Other negative side effects, such as myocardial and respiratory depression, arrhythmias, intrapulmonary shunting, muscle relaxation, and cerebral vasodilation may require supplemental pharmacological interventions that may limit the administered dose \[[@bib17]\]. Hepatic and renal dysfunction can also be a risk during more prolonged cases \[[@bib16]\]. Thus, there are few data available regarding the optimal administration of these agents \[[@bib3],[@bib18]\].

The dominant mechanism of bronchodilation for these agents is not completely understood \[[@bib19]\]. Volatile anesthetics induce direct relaxation of airway smooth muscle (ASM) by the reduction of intracellular free calcium via inhibition of protein kinase C, calcium release from sarcoplasmic reticulum, or voltage-dependent calcium channels \[[@bib20]--[@bib22]\]. In addition, volatile anesthetics are known to reduce the sensitivity of the myofibrillar contractile apparatus to intracellular calcium \[[@bib23]\]. In vivo, bronchodilation with inhaled agents depends on diffusion across the airway wall to reach their pharmacologic site of action \[[@bib24],[@bib25]\]. While this may be most readily achieved via luminal diffusion across the airway wall, systemic uptake and distribution to ASM is also possible via the bronchial or pulmonary circulations. Inhaled anesthetic agents also dilate airways indirectly by reducing vagal tone and reflexes, and by altering β-receptor sensitivity and circulating catecholamines \[[@bib26]--[@bib28]\].

We recently proposed that direct action of inhaled anesthetic agents on ASM would be an effective mechanism for bronchodilation in vivo, and that targeted delivery of these agents to the conducting airways would promote ASM relaxation with a reduction in systemic absorption \[[@bib29]\]. In this study, we hypothesized that diffusion of inhaled anesthetics from airway lumen to ASM would yield significant bronchodilation in vivo, and systemic recirculation would not be necessary to reduce lung resistance and elastance during sustained bronchoconstriction. To test this hypothesis, we developed a novel anesthetic-ventilator system to deliver volatile agents selectively to the conducting airways, or continuously to both the conducting airways and gas exchanging alveolar region. To compare these approaches, we measured lung mechanics and anatomic dead space during sustained cholinergic bronchoconstriction in dogs, before and after continuous and targeted anesthetic delivery.

2. Methods {#s2}
==========

2.1. Anesthetic Delivery System. {#s2A}
--------------------------------

To achieve targeted delivery of the volatile anesthetic to the conducting airways of the lung, we designed and implemented a unique ventilator-valve circuit for precise control of timing and duration of inhaled agent. The inspiratory limb of a transport ventilator (Impact Instrumentation, Inc., West Caldwell, NJ) was divided into two sublimbs (Fig. [1](#F1){ref-type="fig"}). Flow through each sublimb was regulated using computer-actuated solenoid-valves (ASCO Valve, Florham Park, NJ). For targeted delivery, inspiratory flow was initially directed through the bypass sublimb. Following actuation of the solenoid valves, the inspiratory flow was then directed through the second sublimb containing a Universal Portable Anesthesia Complete (U-PAC) drawover vaporizer (Datex-Ohmeda, GE Healthcare, Fairfield, CT). Both sublimbs were rejoined into a single inspiratory limb that was connected to the airway opening.

![Schematic of inhaled anesthetic delivery system. Arrows within the ventilator circuit denote direction of flows. NO Sol, normally open solenoid valve; NC Sol, normally closed solenoid valve; A/D, analog-to-digital converter; D/A, digital-to-analog converter; *P*~ao~, airway pressure; $\overset{˙}{V}$, airway flow. Check valves included to prevent back flow into the inspiratory limb as the gas travels to the scavenger system during expiration.](jesmdt-18-1001_031003_g001){#F1}

Precise switching between sublimbs was accomplished using custom-written data acquisition and control software (National Instruments LabVIEW 2011, Austin, TX). The software estimated the tidal volume (*V~T~*) on a breath-by-breath basis, using trapezoidal integration of the measured flow signal ($\overset{˙}{V}$) \[[@bib30]\]. For volumes below a user-defined threshold volume (*V*~th~), fresh gas was directed through the bypass sublimb. When the delivered volume exceeded *V*~th~, the software actuated a relay driver circuit via a *D*/*A* board. The actuating signal inverted the open/closed configuration of the solenoid valves, forcing the inspiratory gas through the vaporizer sublimb and delivering a bolus of anesthetic agent (with known concentration) in the subsequent portion of *V~T~* though the end of inspiration. Changing the minimum volume *V*~th~ for which the vaporizer was engaged during inspiration, allowed us to vary the timing and duration of anesthetic delivery.

One-way check valves (Hans Rudolph, Inc., Series 1240C, Shawnee, KS) were included in the circuit to ensure a unidirectional flow within the inspiratory limb and to prevent backflow during the expiratory phase. Passive expiration occurred via a bidirectional mushroom valve. Expired gas was directed into an active scavenging system. Precise delivery of the inhaled anesthetic relies on accurate estimates of *V~T~*, which may be influenced by slow drifts, transient fluctuations, gas removal by the side-stream gas analyzer, and other minor fluxes. To minimize these inaccuracies, the numerical integrator was reset to zero at the onset of each new breath, such that *V~T~* was independent of the previous breath and any minor fluctuations. Individual breaths were identified using a numerical breath detector designed to distinguish transitions between inspiration and expiration based on the measured $\overset{˙}{V}$.

2.2. In Vitro Validation. {#s2B}
-------------------------

Proof-of-concept experiments were conducted with the anesthetic ventilator system to quantify inhaled anesthetic delivery to a given dead space volume (*V~D~*). The apparatus consisted of a length of 22 mm ID corrugated tubing with a total volume of about 150 ml, in series with two spring-loaded bellows (IngMar Medical, Ltd. Adult/Pediatric Demonstration Lung, Pittsburgh, PA). This mechanical model simulated a conducting airway or "dead space" compartment, in series with an "alveolar" compartment. During ventilation of the test lung, anesthetic concentrations were measured at the front end ("airway opening"), midpoint, and terminal end ("alveolar/airway mixing interface") of the tubing segment, using a side-stream infrared gas analyzer (Datex-Ohmeda Capnomac Ultima, GE Healthcare).

2.3. Animal Preparation and Measurements. {#s2C}
-----------------------------------------

Animal experiments were conducted in the Animal Research Facility at Beth Israel Deaconess Medical Center, with Protocol \#048-2012 approved by the Institutional Animal Care and Use Committee. Measurements were obtained in five mongrel male dogs weighing between 20 and 25 kg. General anesthesia was induced and maintained with intravenous midazolam (induction dose 10--20 mg, maintenance infusion 0.25 mg kg^−1^ h^−1^) and fentanyl (induction dose 200--250 *μ*g, maintenance infusion 2--5 *μ*g kg^−1^ h^−1^). Each animal was intubated with an endotracheal tube (8.0 mm ID). Neuromuscular blockade was achieved with 1--2 mg intravenous boluses of vecuronium every 10--15 min. Electrocardiogram, oxygen saturation, heart rate were monitored continuously, and noninvasive blood pressure was cycled every 3--5 min. Each animal was ventilated at an initial rate of 20 min^−1^, *V~T~* of 15 ml kg^−1^, and positive end-expiratory pressure (PEEP) of 0 cmH~2~O PEEP. The rate and *V~T~* were titrated to achieve end-tidal CO~2~ pressures between 20 and 40 mmHg. To ensure sufficient oxygenation during bronchoconstriction, animals were ventilated with 100% O~2~ throughout the experiment.

Pressure (*P*~ao~) and flow ($\overset{˙}{V}$) at the airway opening were measured using a pneumotachograph system (Hans Rudolph RSS100-HR, Kansas City, MO), which was appropriately corrected for ventilation with 100% O~2~. An esophageal balloon catheter (Ackrad Labs, Cooper Surgical, Trumbull, CT) was placed in the lower third of the esophagus to measure esophageal pressure (*P*~es~), which served as a surrogate for pleural pressure. Transpulmonary pressure (*P*~tp~) was estimated as the difference between *P*~ao~ and *P*~es~. The *P*~ao~, *P*~es~, and $\overset{˙}{V}$ signals were low-pass filtered at 10 Hz (Frequency Devices, Inc., 90IP, Ottawa, IL), and sampled at 40 Hz using a 12-bit analog-to-digital converter (National Instruments NI UB-6008, Austin, TX). Anesthetic, O~2~, and CO~2~ concentrations were measured at the airway opening using a side-stream infrared gas analyzer (Datex-Ohmeda Capnomac Ultima, GE Healthcare), and digitized using the same *A*/*D* board. All sampled waveforms were stored on a laptop computer (Acer Aspire 5733Z, San Jose, CA).

2.4. Experiment Protocol. {#s2D}
-------------------------

To compare the bronchodilatory efficacy of different inhaled anesthetic delivery regimens and agents, all animals were subjected to four separate experiments applying either targeted or continuous delivery of sevoflurane or isoflurane. Each animal served as its own control. The experimental protocols were applied in random order, with each experiment performed at least one week apart. A description of the experimental protocol is shown in Fig. [2](#F2){ref-type="fig"}. Following intravenous anesthetic induction, baseline measurements of *P*~ao~, *P*~es~, and $\overset{˙}{V}$ waveforms were sampled for 20 breaths. Prior to each measurement of *R~L~*, *E~L~*, and *V~D~*, two deep inspirations were performed to standardize volume history. Sustained bronchoconstriction was then induced with intravenous infusion of methacholine (MCh) at 100 *μ*g min^−1^. A separate intravenous line was used for the MCh infusion, in order to minimize transient effects of the periodic neuromuscular blockade boluses. All pressure and flow measurements were obtained after establishing a sufficient level of steady-state bronchoconstriction \[[@bib31]\].

![Timeline of experimental protocol and drug administration. Baseline measurements of *R~L~*, *E~L~*, and *V~D~* were obtained after anesthetic induction and intubation. Intravenous MCh was then used to induce sustained bronchoconstriction, followed by either targeted or continuous delivery of the inhaled anesthetic. Intravenous atropine was administered after treatment with inhaled anesthetic. Neostigmine and glycopyrrolate were used at the end of the protocol, to reverse neuromuscular blockade.](jesmdt-18-1001_031003_g002){#F2}

Following bronchoconstriction with MCh, either targeted or continuous inhaled anesthetic delivery was initiated and maintained for a total of 20 min. Pressure and flow waveforms were recorded at 10 and 20 min during this period. Inhaled anesthetic concentration was manually adjusted on the U-PAC vaporizer, to attain peak values of 1--2 minimum alveolar concentration (MAC) for dogs \[[@bib32]\]. During continuous delivery, intravenous midazolam and fentanyl infusion rates were decreased based on blood pressure, to maintain appropriate anesthetic depth. The MCh infusion was suspended at the conclusion of the experiment, and each animal was administered a 4 mg intravenous of atropine for maximal bronchodilation. Reversal of neuromuscular blockade was achieved with intravenous boluses of glycopyrrolate (0.2 mg) and neostigmine (1.5 mg). After final measurements of *P*~ao~, *P*~es~, and $\overset{˙}{V}$, each animal emerged from general anesthesia and was extubated. In order to ensure animal safety and anesthetic depth, as well as deliver appropriate inhaled anesthetic during either targeted or continuous delivery, the investigators were not blinded to condition.

2.5. Data Analysis. {#s2E}
-------------------

The sampled *P*~tp~, *V*, and $\overset{˙}{V}$ waveforms were fitted to a single-compartment model using multiple linear regression \[[@bib30]\] $$P_{\text{tp}} = R_{L}\overset{˙}{V} + E_{L}V + P_{0}$$

where *R~L~* and *E~L~* are lung resistance and elastance, respectively, and *P*~0~ is the transpulmonary pressure at end-expiration. Prior to each regression, airway pressure measurements were corrected for nonlinear effects of the endotracheal tube \[[@bib33]\].

Changes in *V~D~* were estimated for each breath using the technique of volume capnography \[[@bib34]\]. Briefly, a volume capnogram for each breath was divided into three phases (Fig. [3](#F3){ref-type="fig"}) corresponding to: (I) resident gas in the conducting airways at the end of inspiration; (II) gas mixing at the interface between terminal bronchi and alveoli; and (III) gas expired primarily from the alveoli. A vertical line parallel to the *y*-axis of the capnogram was placed through phase II, such that the area to the left of the vertical line and below the curve was equal to the area to the right of the vertical line and between the curve and a line tangent to the linear portion of phase III. Total *V~T~* was then divided into an anatomic dead space volume (*V~D~*) and an effective "alveolar" tidal volume (*V*~alv~). From the capnogram, the volumes along the *x*-axis to the left and right of the vertical line were assumed to correspond to *V~D~* and *V*~alv~, respectively.

![Real-time estimation of anatomic dead space using the technique of volume capnography in a representative dog; this analysis was automated for each breath as part of the solenoid-valve control software. A line tangent to phase III (sloping upward dashed) and a vertical line through phase II (vertical dashed) are positioned such that areas *p* and *q* are equal. Volumes along the *x*-axis to the left and right of the vertical line are assumed to correspond to the dead space volume (*V~D~*), and the effective alveolar volume (*V*~alv~), respectively.](jesmdt-18-1001_031003_g003){#F3}

To compare the quantities of inhaled anesthetic each animal received during the targeted or continuous delivery regimens, the anesthetic dose was monitored on a breath-by-breath basis by plotting the concentration of anesthetic agent (*C*~agent~) as a function of *V~T~*. The volume of anesthetic agent inhaled during each breath (*V*~agent~) was estimated by numerical integration of the inspiratory portion of the resulting curve.

2.6. Statistics. {#s2F}
----------------

One-way repeated measures analysis of variance (ANOVA) was used to compare estimates of *R~L~*, *E~L~*, and *V~D~* for targeted and continuous delivery of both sevoflurane and isoflurane. Two-way repeated measures ANOVA was used to compare the inhaled anesthetic dose per breath, with factors selected to be (1) targeted or continuous delivery, and (2) the time point of measurement. If significance was obtained with ANOVA, post hoc analysis was performed using the Holm--Sidak criterion. For each measurement condition, comparisons of *R~L~*, *E~L~*, and *V~D~* were made for targeted and continuous delivery using two-tailed paired *t*-tests. For all comparisons, *P* \< 0.05 was considered statistically significant. Sample size necessary to detect significant changes in *R~L~* during MCh infusion was estimated based on our previous experience with pharmacologically induced bronchoconstriction in dogs \[[@bib31],[@bib35]\]. All model fits, parameter estimations, and statistical analyses were performed using either [matlab]{.smallcaps} R2012a (The Mathworks, Inc., Natick, MA) or SigmaPlot 12.3 (Systat Software, Inc., San Jose, CA).

3. Results {#s3}
==========

3.1. In Vitro Validation. {#s3A}
-------------------------

Characteristic traces of $\overset{˙}{V}$, *V~T~*, and isoflurane concentrations during targeted delivery to a length of corrugated tubing in series with spring-loaded bellows is shown in Fig. [4](#F4){ref-type="fig"}. Isoflurane was not detectable at the interface between the medical tubing and the spring-loaded bellows, indicating that the anesthetic was constrained to the simulated dead space volume. We also found that the concentration of isoflurane within the tubing decreased longitudinally, from the airway opening to the "alveolar" compartment. Moreover, we importantly observed that the concentration of isoflurane at end-expiration was negligible for each sampling location, indicating that the majority of the delivered anesthetic was removed after each breath.

![Isoflurane was delivered to a section of corrugated tubing (∼150 ml, gray cylinder) in series with a pair of spring-loaded bellows (as shown on the right in the schematic), ventilated with tidal volume 500 ml and rate 20 min^−1^: (*a*) characteristic trace of flow measured for two breaths; (*b*) corresponding tidal volume (solid) with real-time generation of actuating signal denoting anesthetic delivery window at the end of inspiration (dashed). The delivery threshold (*V*~th~) was set to 300 ml to account for the delay in switching between sublimbs and engaging the anesthetic vaporizer; and (*c*) three traces of isoflurane concentration characterizing anesthetic distribution throughout the dead space compartment. Isoflurane concentration detected at the interface between dead space and alveolar compartments was negligible.](jesmdt-18-1001_031003_g004){#F4}

3.2. Targeted Versus Continuous Delivery. {#s3B}
-----------------------------------------

Figure [5](#F5){ref-type="fig"} summarizes *R~L~*, *E~L~*, and *V~D~* for all five dogs under baseline conditions, after maximal bronchoconstriction with MCh, at 10 and 20 min of inhaled anesthetic delivery, and following reversal of bronchoconstriction with atropine. Compared to baseline, we found that MCh significantly increased *R~L~* and *E~L~*, and decreased *V~D~* prior to delivery of either isoflurane or sevoflurane, consistent with pharmacologically induced bronchoconstriction. Examples of *R~L~*, *E~L~*, and *V~D~* for the same conditions in two representative dogs are shown in Fig. [6](#F6){ref-type="fig"}. Although *R~L~* and *E~L~* did demonstrate decreases for some dogs during anesthetic delivery (Fig. [6](#F6){ref-type="fig"}), overall these changes did not result in significant differences for the population. Thus, there were no statistically significant changes for any of the parameters between the maximally constricted state and following delivery of the anesthetic agent. We also did not observe significant differences between targeted and continuous delivery for any of the measurement conditions. Discontinuation of MCh, followed by administration of intravenous atropine, returned *R~L~*, *E~L~*, and *V~D~* to similar levels to their respective baseline values, consistent with reversal of bronchoconstriction.

![Summary of: (*a*) and (*b*) lung resistance (*R~L~*); (*c*) and (*d*) lung elastance (*E~L~*); and (*e*) and (*f*) anatomic dead space (*V~D~*) during targeted and continuous delivery. Data are shown for sevoflurane (left panels) and isoflurane (right panels), and are averaged across all animals, with error bars denoting standard deviations. \*Significantly different compared to baseline; ^\#^significantly different compared to atropine. For all comparisons, *P* \< 0.05.](jesmdt-18-1001_031003_g005){#F5}

![Examples of (*a*) and (*b*) lung resistance (*R~L~*); (*c*) and (*d*) lung elastance (*E~L~*); and (*e*) and (*f*) anatomic dead space (*V~D~*) during targeted and continuous delivery for two representative dogs. Data are shown for a positive responder (left panels) and a nonresponder (right panels) during targeted and continuous sevoflurane delivery. Symbols denote the mean value from 20 breaths. Errors bars, when larger than the symbol, denote standard deviations.](jesmdt-18-1001_031003_g006){#F6}

3.3. Delivered Dose of Anesthetic. {#s3C}
----------------------------------

Figure **[7](#F7){ref-type="fig"}** shows sevoflurane and isoflurane concentrations, along with corresponding tidal volumes, for two breaths in a representative dog. Data are shown for both targeted and continuous delivery. Compared to continuous delivery, the initial increase in concentration during targeted delivery was delayed until nearly halfway through inspiration, consistent with the delivery threshold, and reached peak concentration at end-inspiration. This delay resulted in considerably lower end-expiration concentrations for targeted delivery, with profiles of isoflurane being similar. By restricting delivery to the end of inspiration, the dogs were exposed to lower doses of inhaled anesthetic for the targeted condition compared to continuous; the average inhaled anesthetic dose per breath following 10 and 20 min of targeted and continuous delivery of sevoflurane and isoflurane are summarized in Fig. [8(*a*)](#F8){ref-type="fig"}. Doses were similar across animals and were comparable after 10 and 20 min of delivery for a given agent and regimen. Similarly, end-expiratory concentrations were significantly reduced during targeted delivery, while end-inspiratory concentrations were generally similar despite a slightly increased concentration during continuous sevoflurane (Figs. [8(*b*)](#F8){ref-type="fig"} and [8(*c*)](#F8){ref-type="fig"}).

![Example concentration profiles of sevoflurane (solid line) and isoflurane (solid line) measured at the airway opening during (*a*) and (*c*) targeted and (*b*) and (*d*) continuous delivery, superimposed on corresponding tidal volumes (dashed black line). Note the relatively higher end-expiration concentration for continuous compared to targeted delivery.](jesmdt-18-1001_031003_g007){#F7}

![Comparison of: (*a*) average inhaled anesthetic dose per breath; (*b*) end-inspiratory anesthetic concentration; and (*c*) end-expiratory anesthetic concentration measured during targeted and continuous delivery. Data are shown for sevoflurane (left bars) and isoflurane (right bars). Data are averaged across animals, with error bars denoting SD. \*Significantly greater compared to targeted sevoflurane or isoflurane delivery at both 10 and 20 min, *P* \< 0.05.](jesmdt-18-1001_031003_g008){#F8}

4. Discussion {#s4}
=============

In this study, we hypothesized that targeted delivery would promote sufficient anesthetic diffusion directly across the airway wall to reach ASM, resulting in direct relaxation and dilation of constricted airways \[[@bib20]--[@bib22]\]. We used a computer-actuated ventilator-valve circuit to deliver tidal volumes with variable inhaled gas concentrations, and compared estimates of lung resistance, elastance, and anatomic dead space following targeted and continuous delivery of sevoflurane and isoflurane in dogs during cholinergic bronchoconstriction. Our intent was to demonstrate that systemic recirculation of the drug may not be necessary to reduce *R~L~* and *E~L~*. While our data indicate that targeted delivery to the conducting airways lowered systemic absorption of the agent, we were unable to demonstrate that targeted or continuous delivery of inhaled anesthetics at clinically relevant doses were successful at reversing cholinergic bronchoconstriction.

Inhaled anesthetics are potent bronchodilators that promote relaxation of ASM \[[@bib3]--[@bib7],[@bib13]\]. Their neutrally-mediated effects are important contributors to bronchodilation \[[@bib26],[@bib27]\], as clinically relevant concentrations have been shown to depress bronchoconstriction induced using either nebulized acetylcholine or vagal nerve stimulation \[[@bib28]\], while systemic recirculation via the bronchial or pulmonary circulations may also be required for adequate delivery to under-ventilated regions of the lung \[[@bib36]--[@bib38]\]. In addition to these effects, direct diffusion of these agents from lumen to airway wall may be an important mechanism for in vivo bronchodilation. Despite their bronchodilator action, however, we observed that neither targeted nor continuous inhaled anesthetic delivery resulted in significant changes in any of the measured parameters. This is in contrast to previous reports. Ishikawa et al. showed that isoflurane and sevoflurane yielded reductions in *R~L~* and *E~L~* during MCh-induced bronchoconstriction in dogs \[[@bib39]\], with estimates of effect size using Cohen\'s *d* ranging between 0.6 and 0.8 for isoflurane or sevoflurane at 0.5 or 1.0 MAC. Mitsuhata et al. showed comparable effects in reversing anaphylaxis in dogs sensitized to ascaris suum \[[@bib40]\], while other studies have demonstrated comparable protective effects of both inhaled anesthetics in smaller species such as rats and guinea pigs with MCh-induced bronchoconstriction \[[@bib41],[@bib42]\].

There may be several reasons we were unable to detect significant changes in *R~L~*, *E~L~*, or *V~D~* across our cohort. First, the study (*N* = 5) may have been underpowered compared with previous work in which considerably larger animal populations (*N \>* 20) were used \[[@bib39],[@bib40]\]. Although some dogs did demonstrate positive responses to inhaled anesthetic delivery (i.e., reductions in *R~L~* and *E~L~* with increases in *V~D~*), other dogs demonstrated no response at all (Fig. [6](#F6){ref-type="fig"}). For these nonresponders, continuous MCh infusion may have induced excessive levels of bronchoconstriction that was unresponsive to dilation with inhaled anesthetics. It is possible that these agents are more effective as broncho-protective therapy \[[@bib40],[@bib43]\] to prevent rather than to reverse cholinergic bronchoconstriction. Alternatively, we may not have achieved sufficient bronchodilation to result in changes in *R~L~*, *E~L~*, and *V~D~* that were substantial enough to overcome inter- and intrasubject variability in these parameters. It is possible that the total inhaled anesthetic delivered may have been inadequate to achieve equal bronchodilation in each case, either due to insufficient time of administration or delivery concentration. The previously mentioned studies report an increasing dose--response relationship for inhaled anesthetic agents such that larger reductions in *R~L~* and *E~L~* occur for higher MAC. Although we demonstrate similar peak anesthetic concentrations, these increases occur rapidly at the end of inspiration during targeted delivery (Figs. [7(*a*)](#F7){ref-type="fig"} and [7(*c*)](#F7){ref-type="fig"}), and our ventilator-value configuration produced fluctuations between end-inspiration and end-expiration concentrations within a single breath during continuous delivery (Figs. [7(*b*)](#F7){ref-type="fig"} and [7(*d*)](#F7){ref-type="fig"}). Thus, the total dose delivered of inhaled anesthetic with the potential to reach and act on the ASM yielding bronchodilation, especially during targeted delivery, would be smaller than that delivered using a standard anesthesia machine at comparable MAC. Finally, the single compartment model used here may oversimplify representations of the heterogeneity induced by the bronchoconstriction and be insensitive to bronchodilatory changes occurring during treatment with inhaled anesthetics as total lung resistance *R~L~* may be more reflective of parenchymal tissue resistance rather than airway resistance \[[@bib44],[@bib45]\]. Although both may be affected by bronchoconstricting or bronchodilating agonists \[[@bib46],[@bib47]\], inhaled anesthetic delivery in animal models has been shown to cause airway dilation with little change in the parenchymal mechanics \[[@bib43],[@bib48]\]. Dynamic lung elastance *E~L~* may also be directly affected by pharmacologic agonism, and be further modulated by airway-tissue interdependence \[[@bib35]\]. Therefore, more complex, robust analyses such as forced oscillatory measurements of lung impedance \[[@bib30],[@bib49]\] coupled with an inverse model topology \[[@bib31],[@bib50],[@bib51]\] may better characterize mechanical heterogeneity compared to the single compartment model by distinguishing between distributed airway or tissue properties.

4.1. Ventilation Heterogeneity During Bronchoconstriction. {#s4A}
----------------------------------------------------------

One may further speculate that an uneven distribution of the inhaled anesthetic could have played a critical role in the observed variability between positive and negative responses during bronchoconstriction. Previous modeling studies have shown that asthma is associated with heterogeneous constriction of the airway tree, particularly in *smaller* peripheral airways \[[@bib52]--[@bib55]\], though imaging studies suggest that partial closure of *larger* bronchi also contribute \[[@bib56]--[@bib58]\]. Venegas et al. \[[@bib59],[@bib60]\] have shown that "bi-stable" terminal airways, which exist as either fully opened or nearly closed, can lead to poorly ventilated lung regions called ventilation defects \[[@bib50]\] via dynamic feedback interactions involving both the central bronchi and peripheral airways \[[@bib59],[@bib61]\]. Consequently, flow redistribution away from such ventilation defects would promote more heterogeneous delivery of the inhaled anesthetic, causing bronchodilation of unaffected airways, which may limit the overall efficacy of these agents, or even potentially increase ventilation heterogeneity. These increases in airway heterogeneity may contribute to substantial increases in apparent *R~L~* and *E~L~* as measured at the airway opening, especially at physiologic breathing frequencies \[[@bib55]\], which would potentially mask our ability to detect any bronchodilation resulting from direct action of the inhaled anesthetic on ASM. Similarly, MCh-induced hypersecretion of mucus in the airways \[[@bib62]\] may facilitate partial or complete airway closure and formation of mucus plugs \[[@bib63],[@bib64]\], which would occlude small airways and limit the amount of inhaled anesthetic reaching constricted airways. Such an effect would limit the effectiveness of this delivery method and may have played a role in cases where *R~L~* and *E~L~* actually increased and *V~D~* decreased.

4.2. Anesthetic Delivery System. {#s4B}
--------------------------------

We previously proposed that the serial composition of an inspired gas could be manipulated to target the anatomic dead space \[[@bib29]\]. The concept of different portions of the inspired tidal volume having variable gas concentrations is familiar to anesthesiologists using traditional "Mapleson" style semi-open breathing circuits \[[@bib65]\]. In a similar study of serial gas manipulation, Brogan et al. \[[@bib66]\] demonstrated that ventilation--perfusion matching could be improved by application of CO~2~ to the conducting airways exclusively, with targeted delivery achieved by manual injection of CO~2~ during the second half of inspiration. Our anesthetic delivery system advances this method by providing an automated delivery window based on volume capnography, which can be varied to match the subject\'s dead space volume. Such a delivery method is not possible with conventional anesthesia machines, which operate via circular breathing circuits designed to maintain a constant agent concentration. While uncommon in general clinical practice, draw-over anesthesia relies on "pulling" fresh gas across a vaporizer during spontaneous breathing of the patient \[[@bib67]\]. By combining the U-PAC vaporizer in series with a ventilator, fresh gas can be "pushed" across the vaporizer, facilitating rapid response for targeted delivery of the inhaled anesthetic. The reduced size, compatibility with multiple agents, and operational simplicity of the U-PAC vaporizer provides an ideal method for the delivery of inhaled anesthetics in clinical settings, where there are limited options available for administration of these agents to patients \[[@bib6]\].

4.3. Inhaled Anesthetic Exposure. {#s4C}
---------------------------------

Compared to continuous delivery, we found that targeted delivery resulted in a significantly reduced dose of inhaled anesthetic, as well as a lowered residual concentration at end-expiration (Figs. [7](#F7){ref-type="fig"} and [8](#F8){ref-type="fig"}). This suggests that restricting inhaled anesthetics to the end of inspiration facilitated delivery to the conducting airways while decreasing systemic uptake and redistribution, which is an important consideration given that the consistent clinical use of these agents can be limited by negative systemic side effects \[[@bib1]\]. However, a small concentration of end-tidal anesthetic during targeted delivery was still detected (Fig. [8](#F8){ref-type="fig"}), suggesting that some alveolar delivery and/or uptake of anesthetic via the conducting airways may have occurred \[[@bib28],[@bib37]\]. Since the canine airway tree is highly asymmetric and leads to a distribution of path lengths between the trachea and terminal alveoli \[[@bib61]\], a delivery profile appropriate for longer path lengths would have the potential of anesthetic reaching alveoli at shorter distances relative to the airway opening. While these factors may have resulted in some systemic absorption during targeted delivery, the corresponding end-expiratory concentration was considerably lower compared to that for continuous delivery, consistent with lower systemic absorption of the anesthetics, although not directly measured here.

4.4. Model Critique. {#s4D}
--------------------

Our estimate of anatomic dead space, *V~D~*, is an idealized, compartmentalized physiologic construct based on capnography, rather than true anatomic measurements of airway size \[[@bib31]\]. Increased *V~D~* as an index of bronchodilation may be limited in cases where the lung periphery is the most dominant contributor to increased resistance \[[@bib35],[@bib47]\], since the conducting airways constitute the majority of anatomic dead space. Yet we observed that changes in *V~D~* and *R~L~* were closely related during maximal bronchoconstriction and airway relaxation with atropine. Therefore, imaging modalities such as high-resolution computed tomographic and magnetic resonance imaging can provide further insight into the ventilation distribution and degree of heterogeneity during bronchoconstriction, while potentially resolving disparities between trends in lung resistance and anatomic dead space \[[@bib31]\]. Additionally, these experiments focused on the dilation of constricted airways during cholinergic agonism. Methacholine has been shown to constrict the central airways predominantly, whereas an allergen-induced bronchoconstriction leads to a more peripheral pattern of constriction that can manifest through important ventilation defects as discussed previously \[[@bib68]\]. The effects of inhaled anesthetics on this cholinergic pathway may not be similar to their effects on allergic bronchial hyperresponsiveness, for which they are known to be therapeutic \[[@bib69],[@bib70]\].

5. Conclusions {#s5}
==============

Despite the known clinical efficacy of inhaled anesthetics for the treatment of severe bronchoconstriction, we did not observe significant in vivo bronchodilation following either targeted or continuous delivery of these agents during purely cholinergic bronchoconstriction. Given that this is contrary to previous work, we speculate that higher concentrations delivered to ASM may be necessary to achieve significant bronchodilation using these regimens. Protective flow redistribution and hypersecretion of mucus could have limited the amount of inhaled anesthetic delivered to constricted airways, while corresponding increases in lung heterogeneity may have led to increased apparent lung resistance and elastance in some cases. More robust estimates of lung mechanics could help to resolve these discrepancies. Nevertheless, although we were unable to detect significant bronchodilation during inhaled anesthetic delivery, our targeted delivery system indicates that it is possible to deliver inhaled anesthetics predominately to the anatomic dead space, resulting in reduced systemic dose. Thus it may be possible to achieve direct pharmacologic action on airway smooth muscle, with less potential for systemic absorption.
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Nomenclature
============

*C*~agent~ =

:   anesthetic agent concentration

*E~L~* =

:   lung elastance

MCh =

:   methacholine

*P*~ao~ =

:   airway opening pressure

*P*~es~ =

:   esophageal pressure

*P*~tp~ =

:   transpulmonary pressure

*P*~0~ =

:   transpulmonary pressure at end-expiration

*R~L~* =

:   lung resistance

*V* =

:   volume

$\overset{˙}{V}$ =

:   airway opening flow

*V*~agent~ =

:   anesthetic agent volume

*V*~alv~ =

:   alveolar tidal volume

*V~D~* =

:   anatomic dead space

*V~T~* =

:   tidal volume
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